Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.51 |
| ▸ | ERN1 | O75460 | 2/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.50 |
| ▸ | TOP1 | P11387 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18805529 | 0.87 | GRM4 (0.62) | ACVR1GRM4MAPTMAPK14RECQL | |
| SCHEMBL31014179 | 0.87 | GRM4 (0.62) | ACVR1GRM4MAPTMAPK14RECQL | |
| SCHEMBL5318173 | 0.87 | GRM4 (0.62) | ACVR1GRM4MAPTMAPK14RECQL | |
| SCHEMBL12074247 | 0.84 | CA12 (0.65) | CA12CA1CA2CA9ACVR1 | |
| SCHEMBL4658401 | 0.83 | CA12 (0.59) | CA12CA1CA2CA9ACVR1 | |
| SCHEMBL16247654 | 0.83 | MAP4K4 (0.57) | CA12CA1CA2CA9ACVR1 | |
| SCHEMBL12386951 | 0.82 | CA12 (0.59) | CA12CA1CA2CA9ACVR1 | |
| SCHEMBL6296099 | 0.82 | CA12 (0.59) | CA12CA1CA2CA9ACVR1 | |
| SCHEMBL8011323 | 0.82 | CA12 (0.59) | CA12CA1CA2CA9ACVR1 | |
| SCHEMBL27737402 | 0.82 | CA12 (0.63) | CA12CA1CA2CA9ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1596860-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20060211727-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2006-09-21 | — | — | US | disclosed |
| CN-1774247-A | Novel compounds | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | CN | disclosed |
| EP-1596860-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073628-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239897-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, MAPK1 | CA12 4658/4885CA1 4489/4885CA2 3962/4885 |
| US-20060211727-A1 | Novel compounds | MAPKAPK2, CREBBP, MAPK1 | CA12 4658/4885CA1 4489/4885CA2 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.